Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Epilepsy

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 3 · 42.9%High 3 · 42.9%

Topiramate vs placebo

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

Topiramate leads to higher 50% or greater reduction in seizure frequency (ITT analysis) compared with placebo (high certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 2.71 [2.05, 3.59]
12 studies · 1650 participants
High

Topiramate vs placebo

Seizure freedom · people with drug‐resistant focal epilepsy

Topiramate probably leads to higher seizure freedom compared with placebo (moderate certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 3.67 [1.79, 7.54]
8 studies · 1177 participants
Moderate

Topiramate vs placebo

Treatment withdrawal · people with drug‐resistant focal epilepsy

Topiramate leads to higher treatment withdrawal compared with placebo (high certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 2.37 [1.66, 3.37]
12 studies · 1650 participants
High

Topiramate vs placebo

Adverse events ‐ weight loss · people with drug‐resistant focal epilepsy

Topiramate may leads to higher adverse effects ‐ weight loss/decrease compared with placebo (low certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 3.99 [1.82, 8.72]
9 studies · 1070 participants
Low

Topiramate vs placebo

Paraesthesia · people with drug‐resistant focal epilepsy

Topiramate probably leads to higher adverse effects ‐ paraesthesia compared with placebo (moderate certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 3.65 [1.58, 8.39]
7 studies · 1071 participants
Moderate

Topiramate vs placebo

Adverse effects ‐ 'thinking abnormally' · people with drug‐resistant focal epilepsy

Topiramate leads to higher adverse effects ‐ 'thinking abnormally' compared with placebo (high certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 5.7 [2.26, 14.38]
4 studies · 640 participants
High

Topiramate vs placebo

Adverse effects ‐ difficulty with concentration/concentration impaired/concentration‐attention difficulties · people with drug‐resistant focal epilepsy

Topiramate probably leads to higher adverse effects ‐ difficulty with concentration/concentration… compared with placebo (moderate certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 7.81 [2.08, 29.29]
6 studies · 702 participants
Moderate